Scalper1 News
Juno Therapeutics (JUNO), which is developing cutting-edge treatments for cancer, raised the expected price of its initial public offering, indicating strong demand for shares of the biotech company. Juno now looks to raise $203.5 million, up from its previous mark of $153 million. The company hiked its initial public offering’s expected price range to 21-23 from 15-18. The Seattle-based company is developing cellular immunotherapies designed to Scalper1 News
Scalper1 News